Huawei Yang1, Hui Pan2, Fang Yu1, Kai Chen1, Guangwei Shang1, Yuanzhi Xu1. 1. Department of Stomatology, Tenth People's Hospital, Tongji University School of Medicine Shanghai 200072, China. 2. Department of Emergence, Tenth People's Hospital, Tongji University School of Medicine Shanghai 200072, China.
Abstract
OBJECTIVE: To establish a rat model of bisphosphonate-related osteonecrosis of the jaw (BRONJ) that realistically mimics major clinical manifestations of the disease. METHODS: Female Sprague Dawley rats received intravenous zoledronate 80 μg/kg once a week via the tail vein. Three weeks after intravenous injection, maxillary first molars were extracted under general anesthesia. Then 1, 4 and 12 weeks after tooth extraction, the rats were euthanized, and the intact maxillas were harvested en bloc. Macroscopic analysis, histological analysis and cytokine analysis were performed. Untreated rats with tooth extraction were used as controls. RESULTS: 12 weeks after extraction, rats treated with zoledronate developed BRONJ-like disease, including characteristic features of impaired soft tissue healing, exposed necrotic bone or sequestra, increased inflammatory infiltrates, while the controls showed normal bone healing. 4 weeks after extraction, rats treated with zoledronate exhibited the decreased receptor activator of nuclear factor kappa-B ligand (RANKL) values, the increased osteoprotegerin (OPG) values and the remarkable decreased RANKL/OPG ratio when compared with the controls. CONCLUSION: The rats treated with zoledronate can be considered a novel, reliable and reproducible animal model to better understand the pathophysiology and pathogenesis of BRONJ and to develop a therapeutic approach.
OBJECTIVE: To establish a rat model of bisphosphonate-related osteonecrosis of the jaw (BRONJ) that realistically mimics major clinical manifestations of the disease. METHODS: Female Sprague Dawley rats received intravenous zoledronate 80 μg/kg once a week via the tail vein. Three weeks after intravenous injection, maxillary first molars were extracted under general anesthesia. Then 1, 4 and 12 weeks after tooth extraction, the rats were euthanized, and the intact maxillas were harvested en bloc. Macroscopic analysis, histological analysis and cytokine analysis were performed. Untreated rats with tooth extraction were used as controls. RESULTS: 12 weeks after extraction, rats treated with zoledronate developed BRONJ-like disease, including characteristic features of impaired soft tissue healing, exposed necrotic bone or sequestra, increased inflammatory infiltrates, while the controls showed normal bone healing. 4 weeks after extraction, rats treated with zoledronate exhibited the decreased receptor activator of nuclear factor kappa-B ligand (RANKL) values, the increased osteoprotegerin (OPG) values and the remarkable decreased RANKL/OPG ratio when compared with the controls. CONCLUSION: The rats treated with zoledronate can be considered a novel, reliable and reproducible animal model to better understand the pathophysiology and pathogenesis of BRONJ and to develop a therapeutic approach.
Authors: Verena Stresing; Pierrick G Fournier; Akeila Bellahcène; Ismahène Benzaïd; Hannu Mönkkönen; Marc Colombel; F Hal Ebetino; Vincent Castronovo; Philippe Clézardin Journal: Bone Date: 2010-10-20 Impact factor: 4.398
Authors: Ian R Reid; Kenneth Lyles; Guoqin Su; Jacques P Brown; John P Walsh; Javier del Pino-Montes; Paul D Miller; William D Fraser; Susan Cafoncelli; Christina Bucci-Rechtweg; David J Hosking Journal: J Bone Miner Res Date: 2011-09 Impact factor: 6.741
Authors: Akrivoula Soundia; Danny Hadaya; Navid Esfandi; Rafael Scaf de Molon; Olga Bezouglaia; Sarah M Dry; Flavia Q Pirih; Tara Aghaloo; Sotirios Tetradis Journal: Bone Date: 2016-06-18 Impact factor: 4.398
Authors: Thomas Ziebart; Frank Halling; Paul Heymann; Andreas Neff; Sebastian Blatt; Junho Jung; Andreas Pabst; Leonardo Righesso; Christian Walter Journal: Dent J (Basel) Date: 2016-10-25